Universitätsmedizin Berlin and the German Heart Center Foundation announced a research and innovation partnership focused on advancing digital and translational cardiology. The collaboration will bring together world-class clinical cardiovascular expertise at Deutsches Herzzentrum der Charité with BIOTRONIK’s strength in active cardiac devices, artificial intelligence, and connected health technologies. The partnership will span from early-stage ideation to joint development and contract research, and initial projects will focus on developing AI‑driven tools and advanced simulation environments to improve device-based therapies. Press release.
Cirius Therapeutics announced a planning grant from the Gates Foundation to advance the development of CIR‑0602K as a potential postpartum therapeutic for women with a history of gestational diabetes mellitus (GDM). This planning grant can potentially inform a multi‑stage development program to generate scientific and clinical evidence supporting CIR-0602K for postpartum use in women who develop GDM during pregnancy. The initial grant supports a planning and preparation phase for examining potential exposure of CIR-0602K in breast milk, with the objective of enabling future clinical studies in women immediately postpartum, subject to outcomes and regulatory feedback. Press release.
Reimagine Care expanded its AI-enabled virtual oncology care program with Moffitt Cancer Center, building on early outcomes during an initial implementation phase related to patient engagement, symptom management, and acute care utilization. The model extends cancer care beyond scheduled visits through continuous support powered by Reimagine Care’s AI-powered assistant, Remi, and a dedicated oncology virtual care team. Press release.
Verana Health announced its continued investment in women's cancers with the rapid expansion of its ovarian cancer database. The database includes a variable-rich array of curated RWD from both academic and community cancer centers throughout the U.S., offering researchers comprehensive longitudinal insights into disease detection, treatment, and patient outcomes. The ovarian cancer dataset delivers high completeness across critical clinical variables that drive research and treatment decision-making, including molecular testing, treatment sequencing, disease state, and outcomes. Press release.
The Targeted Real-Time Early Warning System, developed by researchers at Johns Hopkins University and commercialized by Bayesian Health has received FDA approval. The system integrates electronic health records with advanced clinical AI to continuously monitor patients and flag sepsis up to 48 hours before a clinician suspects it. A 2022 study of more than 764,000 patient encounters at five US hospitals found that when clinicians acted on the tool’s alerts, sepsis patients were 18% less likely to die in the hospital. Press release.
Myriad Genetics announced the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology. This combination helps identify if a patient is safe for active surveillance (AS) and how refinement of AS intensity can be personalized. This is the only test where each AS metric on patient results was built on studies with untreated patient cohorts. The Prolaris test will continue to help identify patients who are safe for single-modal treatment. Press release.
Oxford Nanopore Technologies and Lonza launched a new technology approach designed to modernize and accelerate GMP quality control testing for mRNA therapeutics. The solution combines direct RNA sequencing using nanopore technology with bespoke machine learning-based data analysis and customized software intended to help close the gap between the rapid pace of mRNA innovation and the slower evolution of analytical methods. Press release.
Mayo Clinic Digital Pathology (MCDP) announced building an integrated innovation ecosystem that supports the future of pathology across clinical care and research. The work reflects Mayo Clinic’s broader digital pathology strategy, including investments in emerging companies, expanded use of digitized pathology data and collaborations designed to improve diagnostic workflows and speed. The initiative is also focused on creating the infrastructure and relationships needed to translate digital pathology innovation into real-world clinical and research impact. Press release.
Personalis announced that the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program has expanded coverage for the company’s NeXT Personal minimal residual disease test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy in patients diagnosed with Stage II-III Triple-Negative Breast Cancer or HER2-positive breast cancer. Press release.
Yourgene Health (part of the Novacyt Group) launched Yourgene Insight DPYD assay, an assay utilizing genetic insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with dihydropyrimidine dehydrogenase deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-fluorouracil, commonly used in the treatment of colorectal, head and neck, breast, pancreatic, and stomach cancers. Press release.
Seegene announced the European launch of its new antimicrobial resistance testing product, Allplex MDRO Assay, which is CE marked under the EU In Vitro Diagnostic Regulation. The assay is designed to support the detection of multidrug-resistant organisms (MDROs) associated with healthcare-associated infections. The assay is designed to identify key multidrug-resistant pathogens and associated resistance genes in a single run, enabling rapid simultaneous detection across a broader range of MDRO targets. It also supports rapid first-line screening before the availability of culture-based results, helping enable timely infection prevention and control responses in hospital settings. Press release.
NeuroVision Imaging acquired Durin Life Sciences. The transaction combines Durin’s blood-based biomarker diagnostics platform with NeuroVision’s retinal imaging technology, telehealth infrastructure, and BrainHealth.net patient engagement platform. The combined company will operate under the NeuroVision name. Together, the companies aim to accelerate the development and commercialization of innovative diagnostic solutions for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and related neurological disorders by pairing advanced biomarker science with scalable clinical, data, and patient engagement capabilities. Press release.
Lucent Diagnostics announced a collaboration with Tempus AI. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, with the LucentAD Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform. The collaboration aims to narrow that gap by embedding clinical guideline-directed identification and blood-based biomarker testing options directly into clinical decision-making workflows used by neurologists. Press release.
arcoris bio launched its immunoMUSE kits, based on its breakthrough MUSE biomarker detection platform. With immunoMUSE, researchers can create their own multiplex immunofluorescence panels using their preferred antibodies, combining flexibility with high sensitivity and ease of use. arcoris bio’s MUSE technology enables simultaneous detection of multiple biomarkers with exceptional sensitivity and simplified workflows. Press release.